Atea Pharmaceuticals Announces Board and Executive Changes

Ticker: AVIR · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1593899

Atea Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyAtea Pharmaceuticals, Inc. (AVIR)
Form Type8-K
Filed DateFeb 24, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, executive-compensation

TL;DR

Atea Pharmaceuticals is shuffling its exec team and board, effective Feb 20, 2025.

AI Summary

Atea Pharmaceuticals, Inc. announced on February 20, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, alongside the election of new directors and the appointment of new officers. These changes are effective as of February 20, 2025.

Why It Matters

Changes in a company's leadership and compensation structures can signal shifts in strategic direction or operational focus, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Leadership changes and executive compensation adjustments can introduce uncertainty regarding the company's future strategy and stability.

Key Players & Entities

  • Atea Pharmaceuticals, Inc. (company) — Registrant
  • February 20, 2025 (date) — Date of earliest event reported

FAQ

What specific roles have been affected by the departure of officers or directors?

The filing indicates the departure of certain officers and directors but does not specify the exact roles affected in this section.

Who are the newly elected directors?

The filing mentions the election of directors but does not list their names in this section.

What are the details of the new compensatory arrangements?

The filing notes changes in compensatory arrangements but does not provide specific details within this initial report.

When were these changes officially reported?

The report was filed as of February 24, 2025, with the earliest event reported on February 20, 2025.

What is Atea Pharmaceuticals' primary business?

Atea Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding Atea Pharmaceuticals, Inc. (AVIR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.